参考文献
[1] 胡盛寿 , 高润霖 , 刘力生 , 等 . 《中国心血管病报告 2018》概要 [J]. 中国循环杂志 ,2019,34(3):209-220. DOI: 10.3969/j.issn.1000-3614.2019.03.001.
[2] 中华医学会心血管病学分会心力衰竭学组 , 中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志 ,2018,46(10):760-789. DOI:10.3760/cma.j.issn.0253-3758.2018.10.004.
[3] Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2019,21(10):1169-1186. DOI: 10.1002/ejhf.1531.
[4] Writing Committee, Maddox TM, Januzzi JL Jr, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol, 2021,77(6):772-810. DOI: 10.1016/j.jacc.2020.11.022.
[5] Gu J, Noe A, Chandra P, et al. Pharma cokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)[J]. J Clin Pharmacol, 2010,50(4):401-414. DOI: 10.1177/0091270009343932.
[6] McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)[J]. Eur J Heart Fail, 2013,15(9):1062-1073. DOI: 10.1093/eurjhf/hft052.
[7] Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study[J]. Eur J Heart Fail, 2019,21(8):998-1007. DOI: 10.1002/ejhf.1498.
[8] Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med, 2019,380(6):539-548. DOI: 10.1056/NEJMoa1812851.
[9] Januzzi JL Jr, Prescott MF, Butler J, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction[J]. JAMA, 2019,322(11):1085-1095. DOI: 10.1001/jama.2019.12821.
[10] Desai AS, Solomon SD, Shah AM, et al. Effect of sacubitril-valsartanvs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial[J]. JAMA, 2019,322(11):1077-1084. DOI: 10.1001/jama.2019.12843.
[11] Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs.ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics[J]. Eur J Heart Fail, 2021,23(6):1040-1048. DOI: 10.1002/ejhf.2191.
[12] Chang HY, Feng AN, Fong MC, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world
experience on advanced chronic kidney disease, hypotension, and dose escalation[J]. J Cardiol, 2019,74(4):372-380. DOI: 10.1016/j.jjcc.2019.03.010.
[13] Nordberg Backelin C, Fu M, Ljungman C. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting[J]. ESC Heart Fail, 2020,7(3):1049-1055. DOI: 10.1002/ehf2.12644.
[14] Solomon SD, McMurray J, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med, 2019,381(17):1609-1620. DOI: 10.1056/NEJMoa1908655.
[15] Shah SJ, Cowie MR, Wachter R, et al. Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction[J]. Eur J Heart Fail, 2021[Online ahead of print].DOI: 10.1002/ejhf.2277.
[16] Kuno T, Ueyama H, Fujisaki T, et al. Meta-analysis evaluating the effects of renin-angiotensin-aldosterone system blockade on outcomesof heart failure with preserved ejection fraction[J]. Am J Cardiol, 2020,125(8):1187-1193. DOI: 10.1016/j.amjcard.2020.01.009.
[17] Nie D, XiongB, Qian J, et al.The effect ofsacubitril-valsartan in heartfailure patients with mid-range and preserved ejection fraction: a meta-analysis[J]. Heart Lung Circ, 2021,30(5):683-691. DOI: 10.1016/j.hlc.2020.10.012.
[18] Yaribeygi H, Sathyapalan T, Maleki M, et al. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review[J]. Life Sci, 2020,240:117090. DOI: 10.1016/j.lfs.2019.117090.
[19] Maejima Y. SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function[J]. Front Cardiovasc Med, 2019,6:186. DOI: 10.3389/fcvm.2019.00186.
[20] Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial[J]. Circulation, 2019,139(11):1384-1395. DOI: 10.1161/CIRCULATIONAHA.118.037778.
[21] McMurray J, DeMets DL, Inzucchi SE, et al. The dapagliflozinand prevention of adverse-outcomes in heart failure (DAPA-HF) trial: baseline characteristics[J]. Eur J Heart Fail, 2019,21(11):1402-1411. DOI: 10.1002/ejhf.1548.
[22] Packer M, Anker SD, Butler J, et al. Effect of empagliflozin onthe clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial[J]. Circulation, 2021,143(4):326-336. DOI: 10.1161/CIRCULATIONAHA.120.051783.
[23] Heerspink H, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study[J]. Lancet Diabetes Endocrinol, 2020,8(1):27-35. DOI: 10.1016/S2213-8587(19)30384-5.
[24] Lam C, Karasik A, Melzer-Cohen C, et al. Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study[J]. Diabetes Obes Metab, 2021,23(6):1431-1435. DOI: 10.1111/dom.14356.
[25] Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patientswith diabetes and recent worsening heart failure[J]. N Engl J Med, 2021,384(2):117-128. DOI: 10.1056/NEJMoa2030183.
[26] Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease[J]. N Engl J Med, 2021,384(2):129-139.DOI: 10.1056/NEJMoa2030186.
[27] Sarraju A, Li J, Cannon CP, et al. Effects of canagliflozin oncardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial[J]. Am Heart J, 2021,233:141-148. DOI: 10.1016/j.ahj.2020.12.008.
[28] Heerspink H, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020,383(15):1436-1446. DOI: 10.1056/NEJMoa2024816.
[29] Breitenstein S, Roessig L, Sandner P, et al. Novel sGC stimulators and sGC activators for the treatment of heart failure[J]. Handb Exp Pharmacol, 2017,243:225-247. DOI: 10.1007/164_2016_100.
[30] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2020,382(20):1883-1893. DOI: 10.1056/NEJMoa1915928.
[31] 吴以岭 . 脉络论 [M]. 北京:中国科学技术出版社 , 2010.
[32] Gao RR, Wu XD, Jiang HM, et al. Traditional chinese medicine qiliqiangxin attenuates phenylephrine-induced cardiac hypertrophy via upregulating PPARγ and PGC-1α[J].Ann Transl Med, 2018,6(8):153.DOI: 10.21037/atm.2018.04.14.
[33] Shen S, Jiang H, Bei Y, et al. Qiliqiangxin attenuates adverse cardiac remodeling after myocardial infarction in ovariectomized mice via activation of PPARγ[J]. Cell Physiol Biochem, 2017,42(3):876-888. DOI: 10.1159/000478641.
[34] Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heartfailure[J]. J Am Coll Cardiol, 2013,62(12):1065-1072. DOI: 10.1016/j.jacc.2013.05.035.
[35] Yao W, Cheang I, Liao S, et al. Study protocol for a randomized controlled trial: qiliqiangxin in heart failUre: assESsment of reduction in morTality (QUEST)[J]. BMC Complement Med Ther, 2020,20(1):38. DOI: 10.1186/s12906-020-2821-0.
[36] 廖玉华 , 杨杰孚 , 张健 , 等 . 舒张性心力衰竭诊断和治疗专家共识 [J]. 临床心血管病杂志 ,2020,36(1):1-10. DOI:10.13201/j.issn.1001-1439.2020.01.001.
[37] Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials[J]. Lancet, 2020,396(10244):121-128. DOI: 10.1016/S0140-6736(20)30748-0.
[38] McMurray J, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction?A redefinition ofevidence-based medicine[J]. Circulation, 2021,143(9):875-877. DOI: 10.1161/CIRCULATIONAHA.120.052926.
[39] 国家心血管病医疗质量控制中心专家委员会心力衰竭专家工作组. 2020中国心力衰竭医疗质量控制报告[J].中国循环杂志, 2021, 36(3):221-238. DOI: 10.3969/j.issn.1000-3614.2021.03.002.